Epizyme reported $-35744000 in Net Income for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Net Income Change
Abbott ABT:US USD 1.44B 583M
Agios Pharmaceuticals AGIO:US USD -81747000 10.06M
Amarin AMRN:US USD -5140000 64.82M
Amgen AMGN:US USD 2.14B 826M
Biogen BIIB:US USD 1.13B 76.7M
Bluebird Bio BLUE:US USD -76520000 23.62M
Daiichi Sankyo 4568:JP JPY 39.46B 20.6B
Eisai 4523:JP JPY 3.57B 23.33B
Exelixis EXEL:US USD 73.21M 2.54M
Gilead Sciences GILD:US USD 1.79B 645M
GlaxoSmithKline GSK:LN GBP 10.32B 9.48B
Glaxosmithkline GSK:US GBP 10.32B 9.48B
Karyopharm Therapeutics KPTI:US USD -36324000 12.74M
Macrogenics MGNX:US USD -24813000 16.49M
Merk MRK:US USD 3.25B 696M
Mirati Therapeutics MRTX:US USD -173561000 2.88M
Novartis NOVN:VX USD 1.57B 121M
Novartis NVS:US USD 1.57B 121M
Pfizer PFE:US USD 8.61B 1.3B
Regeneron Pharmaceuticals REGN:US USD 1.32B 463.6M
Seattle Genetics SGEN:US USD -190816000 55.99M
Vertex Pharmaceuticals VRTX:US USD 930.5M 120M
Xencor XNCR:US USD -32759000 1.22M